Zafgen, Inc. (NASDAQ:ZFGN) Director Frances K. Heller bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The stock was bought at an average price of $3.90 per share, with a total value of $39,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Zafgen, Inc. (NASDAQ ZFGN) opened at 3.50 on Friday. The firm’s market cap is $96.19 million. Zafgen, Inc. has a 1-year low of $2.89 and a 1-year high of $5.46. The firm has a 50 day moving average of $3.52 and a 200 day moving average of $3.79.
Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.03. During the same quarter last year, the business posted ($0.55) earnings per share. On average, equities research analysts expect that Zafgen, Inc. will post ($2.23) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Zafgen, Inc. (ZFGN) Director Purchases $39,000.00 in Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/28/frances-k-heller-purchases-10000-shares-of-zafgen-inc-zfgn-stock.html.
Several institutional investors have recently added to or reduced their stakes in ZFGN. JPMorgan Chase & Co. increased its position in shares of Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock worth $2,311,000 after acquiring an additional 447,964 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Zafgen by 1,701.5% in the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after acquiring an additional 186,336 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Zafgen in the first quarter worth $840,000. Dimensional Fund Advisors LP increased its position in shares of Zafgen by 31.8% in the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 140,848 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Zafgen by 15.7% in the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after acquiring an additional 119,902 shares in the last quarter. 48.53% of the stock is owned by institutional investors.
Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Zafgen from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. ValuEngine upgraded shares of Zafgen from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $6.38.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.